NASDAQ:PRME Prime Medicine Full Year Earnings Results & Report $4.34 +0.46 (+11.70%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Prime Medicine reported Full Year earnings on March 7, 2025. The company reported EPS of -$1.65. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterFull YearReport DateMarch 7, 2025TimeBefore Market Opens Prime Medicine EPS ResultsActual EPS-$1.65Consensus EPS N/ABeat/MissN/AOne Year Ago EPS-$2.18EPS Beat Rate2 of last 8 quartersPrime Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Prime Medicine Full Year Earnings FAQ Did Prime Medicine beat earnings estimates for Full Year? Prime Medicine (NASDAQ:PRME) reported earnings of -$1.65 per share for Full Year. The report was announced on Friday, March 7, 2025. Prime Medicine Earnings HeadlinesPrime Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 20263 hours ago | marketscreener.comMPrime Medicine Q3 Loss Narrows, Revenue RisesNovember 12 at 7:03 PM | marketscreener.comMTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 13 at 1:00 AM | Traders Agency (Ad)Earnings Flash (PRME) Prime Medicine, Inc. Reports Q3 Revenue $4.2M, vs. FactSet Est of $1.3MNovember 12 at 7:03 PM | marketscreener.comMPrime Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 12 at 7:03 PM | finance.yahoo.comPrime Medicine Closes $143.7 Million Public Offering of Common StockNovember 12 at 4:31 PM | quiverquant.comQSee More Prime Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email. Email Address About Prime MedicinePrime Medicine (NASDAQ:PRME) is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts. Its technology is rooted in research by geneticist David Liu and colleagues, who helped develop prime editing.View Prime Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
